相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Peptide-Drug Conjugates with Different Linkers for Cancer Therapy
Mona Alas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of a LC–MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study
Catherine Gowland et al.
Bioanalysis (2021)
Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer
Muhammad Muzamil Khan et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Tumor-penetrating therapy for β5 integrin-rich pancreas cancer
Tatiana Hurtado de Mendoza et al.
NATURE COMMUNICATIONS (2021)
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation
Xin Luan et al.
BIOMATERIALS (2021)
Converting peptides into drugs targeting intracellular protein-protein interactions
Gregoire J. B. Philippe et al.
DRUG DISCOVERY TODAY (2021)
Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?
Sandip Basu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Radiolabeling nanomaterials for multimodality imaging: New insights into nuclear medicine and cancer diagnosis
Jianxian Ge et al.
BIOMATERIALS (2020)
Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma
Zheyu Shen et al.
BIOMATERIALS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar et al.
CLINICAL CANCER RESEARCH (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Problem of Diminished cRGD Surface Activity and What Can Be Done about It
Michael C. Robitaille et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads
Gemma E. Mudd et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study
Paul G. Richardson et al.
LANCET HAEMATOLOGY (2020)
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Gavin Bennett et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
NATURE (2020)
Design of integrin αvβ3 targeting self-assembled protein nanoparticles with RGD peptide
Xiangfeng Lv et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Elin Pauwels et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Paul Hoppenz et al.
FRONTIERS IN CHEMISTRY (2020)
177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
Sanjeet Kumar Jaiswal et al.
ENDOCRINE CONNECTIONS (2020)
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study
Christoph Schliemann et al.
CANCERS (2020)
Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel
Feihu Wang et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
Susan L. Samson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
An enumerative algorithm for de novo design of proteins with diverse pocket structures
Benjamin Basanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition
Josefine Graef et al.
DIAGNOSTICS (2020)
[Ga-68]Ga-DOTA-TOC: The First FDA-Approved Ga-68-Radiopharmaceutical for PET Imaging
Ute Hennrich et al.
PHARMACEUTICALS (2020)
MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms
Valentina Gifford et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Devalingam Mahalingam et al.
CANCERS (2019)
Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling
Barbara Valentinis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab
Maria-Victoria Mateos et al.
BLOOD (2019)
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Satya Das et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2019)
Hypoxia-targeted drug delivery
Amit Sharma et al.
CHEMICAL SOCIETY REVIEWS (2019)
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Ute Hennrich et al.
PHARMACEUTICALS (2019)
Independent control of matrix adhesiveness and stiffness within a 3D self-assembling peptide hydrogel
Nathaniel J. Hogrebe et al.
ACTA BIOMATERIALIA (2018)
Peptide-based nanoprobes for molecular imaging and disease diagnostics
Pengcheng Zhang et al.
CHEMICAL SOCIETY REVIEWS (2018)
Nanoparticle transport pathways into tumors
S. M. Moghimi et al.
JOURNAL OF NANOPARTICLE RESEARCH (2018)
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3
Vanesa Gregorc et al.
LANCET ONCOLOGY (2018)
Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma
Claire Provost et al.
Oncotarget (2018)
Oral peptide delivery: Translational challenges due to physiological effects
Puneet Tyagi et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Synthesis and In Vitro Study of a Dual-Mode Probe Targeting Integrin αvβ3
Yali Zhang et al.
NANOSCALE RESEARCH LETTERS (2018)
Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
Shama Dissanayake et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
D. Arosio et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2017)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickstrom et al.
ONCOTARGET (2017)
Exploring the Role of RGD-Recognizing Integrins in Cancer
Markus Nieberler et al.
CANCERS (2017)
Peptide-Drug Conjugate: A Novel Drug Design Approach
Liang Ma et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Ligand-Targeted Drug Delivery
Madduri Srinivasarao et al.
CHEMICAL REVIEWS (2017)
Peptide-drug conjugates as effective prodrug strategies for targeted delivery
Yin Wang et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2016)
[68Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
Roland Haubner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
Stephen A. Deppen et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors
Rohini Sharma et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer
Yuan Sheng et al.
MOLECULAR PHARMACEUTICS (2015)
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
Michael S. Hofman et al.
RADIOGRAPHICS (2015)
A Unified Mechanism for Aminopeptidase N-based Tumor Cell Motility and Tumor-homing Therapy
Chang Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors
Jytte Oxboel et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz et al.
CLINICAL CANCER RESEARCH (2013)
99mTc-Tektrotyd SPECT/MRI in the Diagnosis of a Gastroenteropancreatic Neuroendocrine Tumor
Shahin Zandieh et al.
CLINICAL NUCLEAR MEDICINE (2012)
Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans
Mohan Doss et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Structural basis for multifunctional roles of mammalian aminopeptidase N
Lang Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The Dimer Interface of the Membrane Type 1 Matrix Metalloproteinase Hemopexin Domain CRYSTAL STRUCTURE AND BIOLOGICAL FUNCTIONS
Anna Tochowicz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Li-Chun Sun et al.
CURRENT DRUG DELIVERY (2011)
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
Malin Wickstrom et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Left-Handed Dimer of EphA2 Transmembrane Domain: Helix Packing Diversity among Receptor Tyrosine Kinases
Eduard V. Bocharov et al.
BIOPHYSICAL JOURNAL (2010)
Structure of the Minimal Interface Between ApoE and LRP
Miklos Guttman et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules
Andrew X. Zhang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scan
Arvind Kumar et al.
ANNALS OF NUCLEAR MEDICINE (2009)
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience
Ralf Bieker et al.
BLOOD (2009)
68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
Zhaofei Liu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients
Laura M. Kenny et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Imaging in the era of molecular oncology
Ralph Weissleder et al.
NATURE (2008)
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
I. Buchmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)
M. V. Davi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Investigation of MC3T3-E1 cell behavior on the surface of GRGDS-coupled chitosan
J Li et al.
BIOMACROMOLECULES (2006)
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif
P Di Matteo et al.
MOLECULAR IMMUNOLOGY (2006)
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms
WY Wu et al.
CANCER RESEARCH (2006)
CD13 (aminopeptidase N) can associate with tumor-associated antigen L6 and enhance the motility of human lung cancer cells
YW Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand
JP Xiong et al.
SCIENCE (2002)
Crystal structure of the extracellular segment of integrin αVβ3
JP Xiong et al.
SCIENCE (2001)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
分享论文
